In its latest financial report, Monte Rosa Therapeutics has announced a significant partnership with Novartis, alongside progress in its pipeline of drug candidates. The partnership involves a global ...
4BIO Capital (‘4BIO’) is an international venture capital firm headquartered in London, focused solely on the advanced and emerging therapies sector. The 4BIO team, which has an unrivalled network ...
Novartis expects to increase its annual sales by least 5% per year in the coming years, CEO Vas Narasimhan said in an ...
LSD is a relatively new drug, compared to many others. And its history has been influenced by some unlikely groups.
Fabhalta is the only oral alternative complement pathway inhibitor to selectively target the underlying cause of C3G, an ultra-rare kidney disease with no approved treatments 2-5 Novartis continues to ...
The Drug Discovery Unit (DDU) initiated collaboration this summer on two projects with the Biomedical Research division of Novartis and is extremely proud of this joint effort to drive forward new ...
The orange-holder, more specifically, addressed the fact that Shannon had made the accusation based on some old texts of hers. As Tamra shared during a recent interview at Bravo HQ (you can watch ...
If approved, Kisqali could nearly double the number of patients eligible for CDK4/6 inhibitor adjuvant therapy,” said Patrick Horber M.D., President, International, Novartis. “Together with the recent ...
Novartis Pharmaceuticals Corp. was sued Thursday in federal court by four female pharmaceutical sales managers who say the company discriminated against them based on their age and gender when they ...
As a host of generics circle the gates, Novartis has lost another bid to waylay MSN Pharmaceuticals’ copycat of the Swiss pharma’s top-selling drug Entresto. In a court decision filed this ...
Swiss drugmaker Novartis is pressuring hospitals to stop making homebrew copies of its life-extending radiation therapies for cancer patients, but doctors say their drugs are safe and that the ...
A federal judge rejected Novartis Pharmaceuticals Corp.’s motion to declare as unlawful the FDA’s approval of a rival version of its heart failure drug Entresto. In the sealed memorandum, the judge ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback